Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years old, of any gender
• People who have been diagnosed with an advanced or spreading solid tumour or a type of blood cancer called non-Hodgkin lymphoma, confirmed by a tissue or cell sample, where standard treatments have not worked, are no longer available, or could not be tolerated
• People who have at least one tumour that can be assessed or measured on scans, according to standard measurement guidelines
• People who are reasonably active and able to care for themselves, rated 0 or 1 on a standard fitness scale used in cancer trials (ECOG scale)
• People who are expected to live for at least 3 months
• People whose blood, liver, kidney, and clotting function meet specific minimum levels shown in blood tests (confirm with trial site for exact values)
• People who are able and willing to use reliable contraception during the trial and for at least 120 days after finishing the study drug, and women who could become pregnant must have a negative pregnancy blood test within 7 days before starting the study drug
• People whose treating doctor believes they may benefit from the study drug IBD0333
• People who are willing to sign a consent form showing they understand the nature of the study treatment

Who may not be able to join:

• People who have had a severe allergic reaction to similar protein-based medicines or to ingredients in IBD0333
• People who have previously been treated with a specific type of immune-stimulating antibody therapy targeting a protein called 4-1BB
• People who have received certain cancer treatments too recently before joining — including chemotherapy within 3 weeks, or radiation, biological therapy, hormone therapy, targeted therapy, or immunotherapy within 4 weeks (different timeframes apply to some specific drugs — confirm with trial site)
• People who have taken another experimental cancer drug within 4 weeks before starting the study
• People who have had major surgery or a serious injury within 4 weeks before starting, or who are expected to need planned surgery during the trial
• People who have taken high-dose steroid tablets or other immune-suppressing medicines within 14 days before starting (low-dose local steroids such as eye drops, skin creams, nasal sprays, or inhalers are generally allowed)
• People who have received immune-boosting medicines such as interleukin-2 or interferon within 14 days before starting
• People who have received a live vaccine within 4 weeks before starting
• People who have had a stem cell or organ transplant from another person
• People who still have significant side effects from previous cancer treatments that have not improved to a mild level, with some exceptions such as hair loss or stable thyroid problems (confirm with trial site)
• People who have cancer that has spread to the brain or the lining of the brain, unless it was previously treated, is stable, and has shown no signs of getting worse on scans for at least 8 weeks after treatment and 4 weeks before joining the trial
• People who currently have an active infection that requires treatment through a drip (intravenous antibiotics or antivirals)
• People with a weakened immune system, including those who test positive for HIV
• People with active hepatitis B or active hepatitis C infection, based on specific blood test results (confirm with trial site for exact thresholds)
• People who have a lung condition called interstitial lung disease, with a limited exception for certain cases without active treatment (confirm with trial site)
• People with serious heart conditions, including dangerous heart rhythm problems, a significantly prolonged electrical interval in the heart (QTcF above 470 milliseconds), a recent heart attack, stroke, heart failure, or uncontrolled high blood pressure within the past 6 months
• People with active autoimmune diseases such as lupus, rheumatoid arthritis, or vasculitis — some stable, well-managed conditions may be exceptions (confirm with trial site)
• People who have previously experienced a serious immune-related side effect (grade 3 or higher) from immunotherapy, or a moderate or severe immune-related heart inflammation — an exception may apply for certain thyroid-related immune reactions (confirm with trial site)
• People who have had another cancer in the past or currently, with some exceptions such as certain treated skin cancers, localised prostate cancer, or cervical changes treated successfully with no sign of disease for 2 or more years
• People with uncontrolled fluid build-up in body cavities considered unsuitable by the treating doctor
• People with alcohol or drug dependence
• People with a psychiatric condition or who are unlikely to be able to follow the trial requirements
• People who are pregnant or breastfeeding, or who have a serious illness that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.